BPC-157

What is BPC-157?

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. First characterized by Dr. Predrag Sikiric and his team at the University of Zagreb in the 1990s, BPC-157 has since become one of the most extensively studied healing peptides in preclinical research — with over 300 published studies spanning multiple tissue types and organ systems.

Its name — 'Body Protective Compound' — reflects the breadth of its cytoprotective effects. Unlike targeted pharmaceutical agents, BPC-157 operates through multiple simultaneous pathways, which may explain its extraordinary efficacy across diverse models of tissue injury.

Mechanism of Action

Angiogenesis and Vascular Repair

BPC-157 strongly upregulates VEGF (Vascular Endothelial Growth Factor), driving the formation of new blood vessels at injury sites. Adequate vascularity is the foundational requirement for tissue healing — no regeneration can occur without oxygen and nutrient delivery. By accelerating angiogenesis, BPC-157 creates the vascular infrastructure that all other repair processes depend on.

Growth Hormone Receptor Upregulation

Research demonstrates BPC-157 sensitizes tissue to local growth hormone signaling by increasing the expression of GH receptors on fibroblasts and myocytes. This amplification of existing GH signals accelerates cell proliferation, collagen synthesis, and tissue remodeling at injury sites.

Nitric Oxide System Activation

Upregulation of eNOS (endothelial nitric oxide synthase) produces vasodilation, reduces platelet aggregation, and provides potent mucosal protection in the gastrointestinal tract. This mechanism is central to BPC-157's remarkable gut-protective effects.

FAK-Paxillin Pathway

BPC-157 activates the focal adhesion kinase (FAK)-paxillin pathway that governs cell migration — the critical first step in wound closure, where cells must move to the injury site before new tissue can be laid down.

NF-κB Inhibition

BPC-157 modulates nuclear factor kappa-B, one of the master regulators of inflammation. By reducing pro-inflammatory cytokine production, it resolves the acute inflammatory phase more efficiently and reduces the chronic, low-grade inflammation that impairs long-term tissue quality.

Key Research Findings

Tendon and Ligament Healing

A landmark study in the Journal of Orthopaedic Research demonstrated BPC-157 accelerated Achilles tendon healing by approximately 50% compared to controls, with superior collagen fiber organization and tensile strength in the healed tissue. Multiple subsequent studies confirmed these findings across quadriceps, patellar, and rotator cuff injury models.

Gastrointestinal Protection and Repair

Over 200 published studies examine BPC-157's GI effects. In models of inflammatory bowel disease, gastric ulcers, intestinal fistulas, and NSAID-induced mucosal damage, BPC-157 consistently produces rapid healing. A 2023 systematic review described it as 'potentially the most potent single compound for GI mucosal repair yet characterized.'

Muscle Repair

In muscle tear and crush injury models, BPC-157 treatment reduced healing time by approximately 40% while significantly improving the histological quality of regenerated muscle fibers — with better alignment, vascularity, and reduced fibrotic scar tissue.

Neurological Applications

Emerging research shows BPC-157 crosses the blood-brain barrier and exerts neuroprotective effects in models of traumatic brain injury, spinal cord damage, and dopaminergic neurotoxicity — suggesting potential applications well beyond musculoskeletal repair.

Research Applications

BPC-157 is studied across an exceptionally wide range of preclinical contexts: orthopedic injury models, gastrointestinal research, sports medicine, neuroscience, and cardiovascular protection. Its multi-mechanism profile makes it relevant wherever tissue healing, inflammation resolution, or cytoprotection are the research focus.

*For research use only. Not for human consumption.*